The Secondary Bile acids, Ursodeoxycholic acid and Lithocholic Acid, Protect Against Intestinal Inflammation by Inhibition of Epithelial Apoptosis by Lajczak-McGinley, Natalia K. et al.
Physiological Reports. 2020;00:e14456.    |  1 of 11
https://doi.org/10.14814/phy2.14456
wileyonlinelibrary.com/journal/phy2
DOI: 10.14814/phy2.14456  
O R I G I N A L  R E S E A R C H
The secondary bile acids, ursodeoxycholic acid and lithocholic 
acid, protect against intestinal inflammation by inhibition of 
epithelial apoptosis
Natalia K. Lajczak-McGinley1  |   Emanule Porru2 |   Ciara M. Fallon1 |   Jessica Smyth1 |   
Caitriona Curley1 |   Paul A. McCarron3 |   Murtaza M. Tambuwala3  |   Aldo Roda2,4  |  
Stephen J. Keely1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2020 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.
1Department of Molecular Medicine, Royal 
College of Surgeons in Ireland, Beaumont 
Hospital, Dublin 9, Ireland
2Department of Chemistry, University of 
Bologna, Bologna, Italy
3School of Pharmacy and Pharmaceutical 
Sciences, Ulster University, Coleraine, 
Northern Ireland
4INBB, National Institute of Bio structures 
and Biosystems, Rome, Italy
Correspondence
Stephen J. Keely, Department of Molecular 
Medicine, Royal College of Surgeons in 
Ireland, Education and Research Centre, 
Smurfit Building, Beaumont Hospital, 
Dublin 9, Ireland.
Email: skeely@rcsi.ie
Funding information
Crohn's and Colitis Foundation of America, 
Grant/Award Number: 354322; Science 
Foundation Ireland, Grant/Award Number: 
16-IA-4445
Abstract
Increased epithelial permeability is a key feature of IBD pathogenesis and it has been 
proposed that agents which promote barrier function may be of therapeutic benefit. 
We have previously reported the secondary bile acid, ursodeoxycholic acid (UDCA), 
to be protective in a mouse model of colonic inflammation and that its bacterial me-
tabolism is required for its beneficial effects. The current study aimed to compare 
the effects of UDCA, LCA, and a non-metabolizable analog of UDCA, 6-methyl-
UDCA (6-MUDCA), on colonic barrier function and mucosal inflammation in a 
mouse model of colonic inflammation. Bile acids were administered daily to C57Bl6 
mice by intraperitoneal injection. Colonic inflammation, induced by addition of DSS 
(2.5%) to the drinking water, was measured as disease activity index (DAI) and his-
tological score. Epithelial permeability and apoptosis were assessed by measuring 
FITC-dextran uptake and caspase-3 cleavage, respectively. Cecal bile acids were 
measured by HPLC-MS/MS. UDCA and LCA, but not 6-MUDCA, were protective 
against DSS-induced increases in epithelial permeability and colonic inflammation. 
Furthermore, UDCA and LCA inhibited colonic epithelial caspase-3 cleavage both 
in DSS-treated mice and in an in vitro model of cytokine-induced epithelial injury. 
HPLC-MS/MS analysis revealed UDCA administration to increase colonic LCA lev-
els, whereas LCA administration did not alter UDCA levels. UDCA, and its primary 
metabolite, LCA, protect against intestinal inflammation in vivo, at least in part, by 
inhibition of epithelial apoptosis and promotion of barrier function. These data sug-
gest that clinical trials of UDCA in IBD patients are warranted.
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1 |  INTRODUCTION
Inflammatory bowel diseases, comprised mainly of ul-
cerative colitis, microscopic colitis, and Crohn's disease, 
are chronic and recurring disorders of the intestinal tract 
that are characterized by inflammation of the intestinal 
wall. Collectively, IBDs affect 1%–2% of the population 
in Western societies, although the incidence is rapidly in-
creasing (Windsor & Kaplan, 2019). While the pathogen-
esis of IBD is still not well understood, it is accepted that 
a complex interplay of environmental and genetic factors 
is involved. Depending on the disease severity, symptoms 
vary from abdominal pain to severe diarrhea, ulceration and 
intestinal bleeding, malnutrition, anxiety, and depression. 
Current treatments for IBD make use of a range of anti-in-
flammatory drugs, including aminosalicylates, glucocorti-
coids, immunosuppressants, and biologics, with these drugs 
primarily targeting the mucosal immune system to reduce 
the inflammatory cell influx and dampen the production 
of cytokines, chemokines, and pro-inflammatory chemical 
mediators (Seyedian, Nokhostin, & Malamir, 2019). While 
these drugs can be effective in inducing or maintaining 
remission in patients, their clinical utility is often limited 
by lack of efficacy, development of drug-resistance, or the 
occurrence of serious side effects and new therapeutic op-
tions are still required.
The pathogenesis of IBD is closely associated with in-
creased epithelial permeability to luminal macromolecules 
(Vancamelbeke & Vermeire, 2017). Whether such loss of 
epithelial barrier function is a cause or consequence of dis-
ease is still uncertain but studies, showing that intestinal 
permeability is increased in disease-free first-degree rela-
tives and spouses of patients, suggest it is likely to be a pre-
disposing factor (Soderholm et al., 1999). Epithelial barrier 
function is a complex and multifaceted entity comprised of 
both physical and biochemical components and the factors 
causing its disruption in IBD are still not well understood. 
However, it is well established that central to the mainte-
nance of the barrier is appropriate regulation of epithelial 
cell turnover by apoptosis (Camilleri, 2019). Apoptosis, or 
programmed cell death, is a process that occurs normally 
as differentiating epithelial cells migrate from the crypts 
to the villus tips (or surface of the colon) and are shed into 
the lumen. An appropriate balance between proliferation 
in the crypts and apoptosis at the villus tip/surface is es-
sential to maintaining continuity to the epithelial barrier. 
In conditions of IBD, there is an upregulation of epithelial 
apoptosis leading to disruption of the physical barrier that 
these cells pose at the interface with the luminal contents 
(Michielan & D'Inca,  2015). In turn, barrier dysfunction 
leads to increased permeability to luminal microbes, toxins, 
and allergens, thereby promoting immune cell infiltration 
and activation and amplifying the inflammatory response. 
Given the importance of increased apoptosis and dysregu-
lated epithelial barrier function in the pathogenesis of IBD, 
there is a great deal of interest in its targeting for disease 
treatment. However, to date, there are still no therapeutic 
options which act by directly targeting the epithelium to 
prevent apoptosis in conditions of IBD.
There has long been an association between altered 
levels of luminal bile acids and the pathogenesis of IBD 
(Tiratterra et  al.,  2018), and recent studies suggest that 
bile acids are likely to have a role to play in the enhanced 
epithelial permeability that is associated with disease pro-
gression (Munch, Strom, & Soderholm,  2007; Stenman, 
Holma, & Korpela,  2012). However, unlike other dihy-
droxy bile acids present in the colon, ursodeoxycholic acid 
(UDCA) has long been known to have therapeutic proper-
ties. UDCA, as the bioactive component of bear bile, has 
long been used in Traditional Chinese Medicine to treat a 
wide range of illnesses and more recently chemically syn-
thesized UDCA has been used in Western medicine to treat 
cholestatic liver diseases, such as gallstones and primary 
sclerosing cholangitis (Cabrera, Arab, & Arrese,  2019; 
Wang & Carey,  2014). The therapeutic properties of 
UDCA in the liver have been, at least partly, ascribed to 
its capacity to prevent apoptosis (Amaral, Viana, Ramalho, 
Steer, & Rodrigues, 2009; Beuers, 2006). Indeed, based on 
its potent cytoprotective actions, UDCA is currently under 
investigation for a range of diseases that are associated with 
increased apoptotic cell death, including neurological, oc-
ular, and cardiovascular disorders (Vang, Longley, Steer, & 
Low, 2014).
Several studies have shown that UDCA and its taurine 
conjugate (TUDCA) are protective in preclinical models of 
intestinal inflammation (Kullmann, Arndt, Gross, Ruschoff, 
& Scholmerich, 1997; Laukens et al., 2014; Martinez-Moya 
et  al.,  2013; Van den Bossche et  al.,  2017). In the DSS 
model of intestinal disease, where inflammation is initiated 
due to a breakdown of epithelial barrier function (Eichele 
& Kharbanda, 2017), we have also demonstrated UDCA to 
reduce disease severity and to dampen mucosal cytokine 
expression. (Ward et  al.,  2017). Furthermore, since a met-
abolically stable analogue of UDCA, 6-methyl-UDCA (6-
MUDCA) was without protective effects, we proposed that 
bacterial metabolism of UDCA was necessary for the full 
expression of its beneficial actions. In keeping with this, we 
found that administration of the primary colonic metabolite 
of UDCA, lithocholic acid (LCA), was even more potent than 
its parent compound in protecting mice from DSS-induced 
colonic inflammation. Here, we set out to build on our pre-
vious work by directly comparing the effects of UDCA and 
LCA in the DSS model of colonic inflammation and to inves-
tigate whether these bile acids exert their beneficial actions 
by directly targeting cytokine-induced epithelial apoptosis 
and barrier function.
   | 3 of 11LAJCZAK-MCGINLEY Et AL.
2 |  MATERIALS AND METHODS
2.1 | Animal studies
Ethical approval for experiments carried out on mice 
was obtained from the RCSI Ethics Committee and the 
Health Products Regulatory Authority of Ireland (HPRA; 
Authorization #: AE19127/P047). Male C57Bl/6 mice 
were used between 10 and 12 weeks of age. Colitis was in-
duced in mice by addition of 2.5%DSS (MP Biomedicals, 
Solon, OH) to the drinking water for 6 days. Disease ac-
tivity index (DAI) was used as a measure of disease pro-
gression and was calculated by the addition of scores 
designated to body weight, fecal blood, and stool con-
sistency/diarrhea, as previously described (Tambuwala 
et al., 2015). Starting one day prior to the administration 
of DSS, animals received daily intraperitoneal injections 
of either endotoxin-free PBS (vehicle control), Na+-
UDCA (30  mg/kg), Na+-LCA (30  mg/kg), or Na+-6α-
MUDCA (30  mg/kg) dissolved in PBS. On day 6, mice 
were administered FITC-dextran (6  mg/kg) by oral gav-
age. Mice were sacrificed on day 7 and their colons were 
removed and measured. Cecal contents were collected, 
mixed with an equal volume of isopropanol, and stored 
until analysis for bile acid content. For histological scor-
ing, approximately 1 cm sections of distal colonic tissue 
were fixed in 10% paraformaldehyde (pH 7.4; PBS buff-
ered) and embedded in paraffin. Sections (4 µm) were cut, 
stained with H&E, and blindly examined for histological 
score by 2 independent observers, as previously described 
(Tambuwala et al., 2015). Staining for cleaved caspase-3 
in epithelial cells of colonic sections was carried out using 
anti-cleaved caspase-3 (Asp175) (5A1E) (Cell Signalling 
Technologies). Quantification of epithelial cells stained 
for cleaved caspase-3 was assessed in a blinded fashion 
using Aperio Scanscope software by two independent 
observers.
For measurements of MPO activity, sections of distal 
colonic mucosa were stripped of their smooth muscle and 
epithelial layers, homogenized on dry ice, and assayed 
using a kit according to the manufacturer's instructions 
(Sigma-Aldrich). For measurements of FITC-dextran 
uptake from the lumen, blood was collected by cardiac 
puncture and centrifuged at 1,500g (15 min, 4°C). Levels 
of FITC-dextran in the serum were then measured fluo-
rometrically, according to the manufacturer's instructions 
(Sigma-Aldrich).
2.2 | Cell culture and treatments
T84 colonic epithelial cells were grown in Dulbecco's modi-
fied Eagle's medium (DMEM)–Ham's F12 nutrient mixture 
(1:1), supplemented with 5% fetal bovine serum (FBS), 
1% penicillin/streptomycin, and 1% L-Glutamine (Gibco). 
For measurements of FITC-dextran flux, cells were seeded 
onto 12  mm Milicel-HA Transwell inserts (Milipore, 
Merck) at a density of 5  ×  105 cells/insert. For western 
blot analyses, cells were seeded onto 24 mm Millicell-HA 
cell culture inserts at a density of 2 × 106 cells/insert. Cells 
were cultured on inserts until they attained an electrically 
resistant phenotype, that is, when transepithelial resist-
ance (TEER) reached approximately 1 KΩ/cm2, as meas-
ured using an EVOM2™ Voltohmmeter (World Precision 
Instruments).
2.3 | Measurements of FITC-dextran flux
Cells were washed and incubated in serum-free medium for 
1 hr prior to treatment with IFNγ (40 ng/ml, Peprotech) for 
24 hr. Cells were then treated with TNF (20 ng/ml, Peprotech) 
in combination with either UDCA (100 µM), LCA (10 µM), 
or 6-MUDCA (100  µM). Simultaneously, 5  μl of FITC-
dextran (10  mg/ml) was added to the apical side of the 
Transwell insert. After a further incubation of 24 hr, medium 
from the basolateral side of the cell monolayers was collected 
and fluorescence intensity was measured on a Victor X3 plate 
reader (Perkin Elmer) set to 485 nm excitation and 520 nm 
emission wavelengths.
2.4 | Western blotting
Treated monolayers of T84 cells were scraped from their in-
serts and homogenized in lysis buffer (130 mM glycine, 2% 
sodium dodecyl sulphate [SDS], 7.7% glycerol in 70 mM 
Tris-HCl, pH 8.8) by repeated passage through a 26-gauge 
needle. Samples, normalized for protein content, were mixed 
with an equal volume of 2 × laemmli loading buffer (1/1, 
v/v) (Sigma), boiled for 5 min, and loaded onto a 8% SDS-
tricine polyacrylamide gel. After electrophoresis, transfer 
to PVDF membranes (Millipore) was performed for 2 hr at 
0.15 A in 0.05 M sodium borate solution, pH 9.0, with 20% 
methanol and 0.05% SDS. Immunoblotting was performed 
with antibodies against cleaved-PARP (Catalogue #: 9,546; 
Cell Signalling Technology). Cleaved-PARP levels were 
quantified by densitometry (ImageQuantTLInk software) 
and normalized to β-actin as a protein loading control 
(Abcam).
2.5 | Cecal bile acid analysis
Cecal bile acid levels were identified and quantified by 
high-pressure liquid chromatography-electrospray-mass 
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spectrometry/mass spectrometry (HPLC-ES-MS/MS) by 
recent published method suitable for use in pure stand-
ard solution, intestinal content, and stool samples after 
appropriate pre-analytical procedures. Liquid chro-
matography analysis was performed using an Alliance 
HPLC system model 2695 from Waters combined with 
a triple quadruple mass spectrometer QUATTRO-LC 
(Micromass; Waters) using an electrospray interface. The 
analytical column was a Waters XSelect CSH C18 col-
umn, 5 µm, 150 × 2.1 mm, protected by a self-guard col-
umn Waters XSelect CSH C18 5 µm, 10 × 2.1 mm. BAs 
were separated by elution gradient mode with a mobile 
phase composed of a mixture ammonium acetate buffer 
15  mM, pH 8.0 (Solvent A) and methanol (Solvent B). 
Chromatograms were acquired using the mass spectrom-
eter in multiple reaction monitoring mode. Briefly, ali-
quots of cecal sample homogenate (0.3 g) were extracted 
with 0.9 ml of isopropanol. The mixture was stirred for 
30 min at 37°C, then centrifuged at 800 g for 5 min. The 
supernatant was then diluted 1:10 (v/v) with 40% isopro-
panol in 15 mM ammonium acetate at pH 8.00, filtered, 
transferred to an autosampler vial, and 5 μl injected into 
the HPLC-ESI-MS system.
2.6 | Statistical analysis
Results are expressed as mean ± SEM for a series of n experi-
ments. Statistical analyses were performed by ANOVA with 
the Tukey multiple comparisons post-test using GraphPad 
Instat software (GraphPad). p values ≤.05 were considered 
to be statistically significant.
3 |  RESULTS
3.1 | Analysis of cecal bile acids in mice 
administered UDCA, LCA, or 6-MUDCA
We first analyzed levels of UDCA and LCA in the cecal 
water before and after treatments with the bile acids. Under 
basal conditions, LCA was more prevalent than UDCA 
at 10.1  ±  1.3 and 2.9  ±  1.4  µg/ml, respectively (n  =  12). 
Treatment with DSS tended to increase the levels of UDCA 
and decrease those of LCA but these effects were not statisti-
cally significant. Daily administration of UDCA significantly 
increased cecal UDCA levels to 9.4  ±  1.6  µg/ml (n  =  12; 
p < .01) and LCA levels to 25.9 ± 3.0 µg/ml (n = 12; p < .01). 
Administration of LCA to the mice did not a significantly 
alter cecal UDCA concentrations but increased LCA levels to 
35.4 ± 9.0 µg/ml (p < .001; n = 12). Under basal conditions, 
the primary bile acid, CDCA, was present at relatively low 
amounts (1.0 ± 0.3 µg/mg; n = 12). None of the treatments 
used significantly altered CDCA levels although DSS tended 
to decrease levels of the bile acid. Treatment of the mice with 
the non-metabolizable UDCA analog, 6-MUDCA, did not 
alter levels of LCA or UDCA (Figure 1).
3.2 | UDCA and LCA, but not 6-MUDCA, 
protect against DSS-induced intestinal 
inflammation in mice
Administration of DSS (2.5%) in the drinking water increased 
DAI to 8.4 ± 0.7 by day 7 of the study (Figure 2a). This was 
accompanied by significant weight loss and shortening of the 
F I G U R E  1  Analysis of cecal bile acids in mice administered UDCA, LCA, or 6-MUDCA. Starting 24 hr prior to administration of DSS 
(2.5% in the drinking water), and daily thereafter, separate groups of male C57BL6 mice received endotoxin-free PBS or Na+-UDCA (30 mg/
kg), Na+-LCA (30 mg/kg), or Na+-6α-MUDCA (30 mg/kg) dissolved in PBS by IP injection. On the 7th day, mice were sacrificed and the cecal 
content was collected and analyzed for levels of (a) UDCA, (b) LCA, and (c) CDCA, as described in Materials and Methods. Data are expressed as 
mean ± sem. n = 12; **p < .01, *** p < .001 compared to untreated controls
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colon (Figure 2b and c). Daily treatment with either UDCA 
or LCA significantly attenuated DSS-induced disease activ-
ity to 3.3 ± 0.6 and 4.3 ± 0.7, respectively. However, admin-
istration of 6-MUDCA was without effect. None of the bile 
acids significantly altered DSS-induced weight loss although 
there was a tendency for UDCA to reduce and LCA to in-
crease weight loss. None of the bile acids tested significantly 
altered colonic shortening in response to DSS.
Histological evaluation of the distal colon revealed that 
treatment with DSS increased inflammatory cell infiltration, 
mucosal edema, and epithelial damage leads to an overall in-
crease in the histological inflammation score (Figure 3a and b). 
However, in mice treated with UDCA, the histological score 
was significantly reduced from 26.2 ± 4.0 in mice treated with 
DSS alone to 11.8 ± 0.7 (p < .01; n = 12). Furthermore, in 
mice treated with LCA, the inflammation score was reduced 
by an even greater extent to 3.9 ± 2.9 (p < .001; n = 12). In 
contrast, 6-MUDCA treatment did not significantly alter the 
DSS-induced increase in histological inflammation score. As 
a biochemical index of neutrophil influx to the mucosa, we 
also measured mucosal myeloperoxidase levels. Upon DSS 
treatment, MPO levels increased in the mucosa and this effect 
was significantly reduced by treatment with either UDCA or 
LCA, but not with 6-MUDCA (Figure 3c).
3.3 | UDCA and LCA, but not 6-MUDCA, 
inhibit DSS-induced epithelial apoptosis 
increased mucosal permeability in vivo
Next, we went on to investigate whether the protective effects 
of UDCA and LCA against the onset of colonic inflammation 
might be due to a restoration of epithelial barrier function. To 
assess epithelial permeability, we employed the fluorescent 
marker, FITC-dextran, to measure its appearance in the blood 
after oral administration. Induction of colonic inflammation 
with DSS increased the appearance of FITC-dextran the blood, 
indicating enhanced epithelial permeability to the macromol-
ecule. However, treatment of the mice with either UDCA or 
LCA abolished this effect. In contrast, in 6-MUDCA-treated 
mice, levels of FITC-dextran in the blood were similar to those 
in mice treated with DSS alone (Figure 4a).
Given the importance of regulated cell death in the main-
tenance of intestinal barrier function, we assessed the effects 
F I G U R E  2  Effects of UDCA, LCA, and 6-MUDCA on disease activity in DSS-treated mice. Starting 24 hr prior to administration of DSS 
(2.5% in the drinking water), and daily thereafter, separate groups of male C57BL6 mice received either endotoxin-free PBS or Na+-UDCA 
(30 mg/kg), Na+-LCA (30 mg/kg), or Na+-6α-MUDCA (30 mg/kg) dissolved in PBS by IP injection. (a) Disease activity index (DAI) was assessed 
daily (n = 12). For clarity, the inset depicts DAI at the end of the treatment period on Day 7. (b) Body weight was assessed daily to monitor disease 
progression. (c) Mice were sacrificed on day 7 and their colons were removed and measured (n = 5–6). ***p < .001 compared to controls (no DSS 
treatment); ##p < .001 compared to DSS-treated mice
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of bile acid treatment on DSS-induced apoptosis of the ep-
ithelial layer. For these experiments, we analysed the levels 
of the apoptotic marker, cleaved caspase-3, in the epithelium 
of colonic sections. As expected, administration of DSS in-
creased the levels of cleaved caspase-3 in the colonic epithe-
lium, indicating increased apoptosis. However, this effect was 
significantly attenuated when mice were treated with either 
UDCA or LCA. In contrast, treatment with 6-MUDCA failed 
to prevent DSS-induced caspase-3 cleavage (Figure 4b and c).
3.4 | UDCA and LCA, but not 6-MUDCA, 
inhibit inflammatory cytokine-induced 
increases in colonic epithelial apoptosis and 
permeability in vitro
Finally, to investigate whether the protective effects of UDCA 
and LCA might be due to direct actions on the epithelial cells 
themselves, we employed the T84 colonic epithelial cell line. 
When grown as on permeable supports, these cells form elec-
trically resistant monolayers that provide a well-established 
reductionist model of colonic epithelial barrier function. To 
mimic the inflammatory environment in vivo, cells were 
treated with the pro-inflammatory cytokines, TNF-α, and 
IFN-γ. Under these conditions, cytokine-treated cells under-
went increased apoptosis, as indicated increased levels of 
cleaved PARP by Western blotting, and this was associated 
with significantly increased permeability of the monolayers 
to FITC-dextran (Figure 5). However, in cells treated with 
either UDCA or LCA, cytokine-induced increases in apopto-
sis and FITC-dextran permeability were abolished, whereas 
6-MUDCA was without significant effect.
4 |  DISCUSSION
As we enter into the third decade of the 20th century, the in-
cidence of IBD continues to increase around the world, with 
F I G U R E  3  Effects of UDCA, LCA, and 6-MUDCA mucosal inflammation in DSS-treated mice. Starting 24 hr prior to administration of 
DSS (2.5% in the drinking water), and daily thereafter, separate groups of male C57BL6 mice received endotoxin-free PBS or Na+-UDCA (30 mg/
kg), Na+-LCA (30 mg/kg), or Na+-6α-MUDCA (30 mg/kg) dissolved in PBS by IP injection. (a) Sections of colon from control, DSS-treated and 
bile acid-treated C57BL6 mice were taken and processed for H&E staining. (b) Inflammation score was assessed as described in Materials and 
Methods (n = 3). (c) Sections of distal colon were stripped of their muscle layers and MPO activity was assessed (n = 5–6); **p < .01,***p < .001 
compared to controls (no DSS treatment); #p < 005, ##p < .01, ###p < .001 compared to DSS-treated mice
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Western populations being particularly susceptible (Windsor 
& Kaplan,  2019). While we have learned much about the 
genetic and environmental factors underlying pathogen-
esis of the disease, they are still not fully defined and our 
understanding of the cellular and molecular mechanisms in-
volved is still incomplete. Consequently, despite intensive 
research efforts, the development of new approaches for 
IBD treatment has been lacking. The first line of treatment 
F I G U R E  4  Effects of UDCA, LCA, and 6-MUDCA on barrier function and epithelial caspase-3 cleavage in DSS-treated mice. Starting 24 hr 
prior to administration of DSS (2.5% in the drinking water), and daily thereafter, separate groups of male C57BL6 mice received endotoxin-free 
PBS, Na+-UDCA (30 mg/kg), Na+-LCA (30 mg/kg), or Na+-6α-MUDCA (30 mg/kg) by IP injection. On the 6th day, mice were administered 
FITC-dextran (6 mg/kg) by oral gavage and after a further 24 hr mice were sacrificed. (a) Levels of FITC-dextran in serum samples were 
measured (n = 12). (b) Sections of colon from control, DSS-treated and DSS + bile acid-treated C57BL6 mice were taken and processed for 
immunohistochemical staining with Cleaved Caspase-3 antibody (n = 3) *p < .05, ***p < .001 compared between indicated groups
F I G U R E  5  Effects of UDCA, LCA, and 6-MUDCA on colonic epithelial barrier function in vitro. Monolayers of T84 cells grown on 
permeable supports were treated with IFN-γ (40 ng/ml) 24 hr prior adding TNF (20 ng/ml) alone or in combination with Na+-UDCA (100 µM), 
Na+-LCA (10 µM) or Na+-6α-MUDCA (100 µM). FITC-dextran (10 mg/ml) was then added to the apical side. (a) After 24 hr, the basolateral 
media was collected and FITC-dextran levels were measured (n = 4). (b) Lysates from cells treated with IFNγ and TNF in the absence or presence 
of UDCA, LCA, or 6-MUDCA were analyzed for levels of the p89 fragment of cleaved PARP by western blotting. Panel c shows densitometric 
analysis of 5 similar experiments. ***p < .05 compared to untreated cells; ###p < .001 compared to TNF/IFNγ-treated cells.
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continues to be immunosuppressants, the use of which in 
many patients is limited by lack of efficacy, development 
of resistance, and the occurrence of adverse effects. New 
lines of treatment are still urgently required and there has 
been growing interest in the potential for targeting epithe-
lial barrier function for this purpose. Increased permeability 
of the epithelial layer to luminal macromolecules has long 
been appreciated as an early event in the pathogenesis of dis-
ease in both animal models and humans (Chassaing, Aitken, 
Malleshappa, & Vijay-Kumar,  2014; Kitajima, Takuma, & 
Morimoto, 1999). Indeed, the observations that abnormalities 
in colonic barrier function exist in disease-free first-degree 
relatives of IBD patients suggest that it may be a fundamental 
factor in disease onset (Soderholm et al., 1999). With this in 
mind, it is thought that drugs which target the epithelium to 
promote barrier function may provide an effective alternative 
to currently available treatments (Camilleri, 2019). The cur-
rent studies suggest that the bile acid, UDCA, has potential to 
be developed for use in such a way.
As we and others have previously reported, we found 
UDCA to exert protective actions against DSS-induced co-
lonic inflammation in mice, a model considered to be particu-
larly suitable for studying the role of epithelial barrier function 
in disease pathogenesis (Eichele & Kharbanda, 2017). After 
7 days of DSS treatment, administration of UDCA decreased 
disease activity index by approximately 50% and this was ac-
companied by a similar attenuation of the histological inflam-
mation score. Treatment with UDCA prevented epithelial 
damage and this was accompanied by a functionally restored 
barrier, as demonstrated by reduced flux of FITC-dextran 
from the lumen into the blood after its oral administration. 
This barrier-promoting effect of UDCA was associated with 
reduced influx of granulocytes into the mucosa, as deter-
mined histologically by H&E staining and biochemically, by 
measurements of mucosal MPO levels. Thus, findings from 
the current studies confirm our previous observations and 
support a growing body of evidence to suggest that UDCA 
may have a role to play in the treatment of intestinal inflam-
matory diseases.
In the current study, we have extended our previous work 
to directly compare the effects of UDCA, with that of its 
primary metabolite, LCA, and a non-metabolizable analog, 
6-MUDCA, on inflammation and barrier function in the DSS 
model while measuring colonic levels of these bile acids 
after treatment. We found that similar to UDCA, treatment 
of the mice with LCA attenuated DSS-induced disease activ-
ity and was even more effective in reducing the histological 
inflammation score and mucosal levels of MPO. LCA also 
prevented the DSS-induced increase in mucosal permeabil-
ity to FITC-dextran, demonstrating enhanced epithelial bar-
rier function in response to treatment with the bile acid. In 
contrast, 6-MUDCA was without significant effect on either 
disease activity, histological inflammation score, mucosal 
MPO levels, or FITC-dextran uptake into the blood. Thus, 
our current data confirm previous findings that bacterial 
metabolism of UDCA is necessary for the expression of its 
anti-inflammatory actions in vivo. This is further supported 
by our analysis of cecal bile acid levels in mice treated with 
UDCA, LCA, or 6-MUDCA. In 6-MUDCA-treated mice, 
levels of UDCA and LCA were unchanged and protective ef-
fects against DSS-induced inflammation were not observed. 
In UDCA-treated mice, where protective actions were ob-
served, both UDCA and LCA levels were significantly ele-
vated in the colon. Similarly, protective effects were apparent 
in LCA-treated mice, where only LCA and not UDCA levels 
were elevated in the cecal content. Thus, it appears to be the 
presence of elevated levels of LCA in the colon that is most 
closely associated with protection against colonic inflamma-
tion in this model.
Intestinal barrier function is a complex entity comprised 
of several physical and biochemical factors, most of which 
appear to be disrupted in conditions of IBD (Vancamelbeke 
& Vermeire, 2017). Increased epithelial cell death by apopto-
sis is recognized to play an important role in enhanced muco-
sal permeability, both in animal models and human patients 
(Gunther, Buchen, Neurath, & Becker, 2014; Seidelin, 2015). 
The data presented here demonstrate that treatment with 
UDCA inhibits colonic epithelial apoptosis, both in vitro 
and in vivo. The idea that UDCA can exert anti-apoptotic 
actions is not new, with previous studies demonstrating its 
cytoprotective actions in hepatocytes (Sommerfeld, Reinehr, 
& Haussinger,  2015; Tsagarakis, Drygiannakis, Batistakis, 
Kolios, & Kouroumalis,  2010). To date, there have been 
few studies of the effects of UDCA on apoptosis in entero-
cytes, with these focussing primarily on the protective ef-
fects of the bile acid in preventing apoptotic responses to 
deoxycholic acid (Im, Akare, Powell, & Martinez,  2005; 
Saeki et al., 2012). Only one previous study has investigated 
the actions of the taurine-conjugated derivative of UDCA, 
TUDCA, on cytokine-induced apoptosis in colonic epithelial 
cells where, similar to the current studies, it was found to be 
protective (Laukens et  al.,  2014). However, very high con-
centrations of TUDCA (>5 mM) were required for protective 
effects to be observed, with the authors suggesting that, due 
to lack of uptake mechanisms for luminal bile acids in the 
colon, entry of hydrophilic TUDCA into the cell likely only 
occurs only when its critical micellar concentration (CMC) is 
exceeded. The current study is the first to show that UDCA, 
at levels well below its CMC, can enter the colonic epithe-
lium to directly inhibit cytokine-induced apoptosis. Thus, in 
the setting of colitis, increased barrier function in response to 
UDCA administration would be expected to prevent the entry 
of bacteria and their toxins into the mucosa, thereby allevi-
ating inflammation. It should be noted that the current study 
does not preclude that the barrier-promoting effects of UDCA 
and LCA may not only be due to inhibition of apoptosis but 
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may also involve the preservation of tight junction integrity. 
Epithelial tight junctions are known to become dysregulated, 
with increased permeability to macromolecules, in condi-
tions of inflammation and future studies should be conducted 
to assess how UDCA and LCA may impact this.
Since, 6-MUDCA was without effect on colonic epi-
thelial apoptosis in vivo, while LCA had similar protective 
actions to UDCA, our data support a model in which bacte-
rial conversion of UDCA to LCA is necessary for it to exert 
anti-apoptotic actions. These data complement our previous 
studies in which we found that LCA also potently inhibits the 
release of pro-inflammatory cytokines from the colonic epi-
thelium (Ward et al., 2017), and contradict the classical view 
of LCA being a “toxic” bile acid. While it is clear that when 
present at high concentrations, LCA can induce epithelial 
apoptosis (Katona, Anant, Covey, & Stenson, 2009), its role 
in regulating barrier function at lower concentrations needs 
to be reconsidered. Interestingly, previous studies have re-
ported that colonic LCA levels are suppressed in DSS-treated 
mice (Araki, Andoh, Tsujikawa, Fujiyama, & Bamba, 2001; 
Van den Bossche et al., 2017), suggesting the bile acid may 
have a role to play in dampening the inflammatory response. 
Furthermore, levels of Clostridial bacterial strains that pos-
sess the 7-β-hydroxylase enzymatic activity required to 
convert UDCA to LCA have been shown to be decreased in 
patients with IBD (Paramsothy et al., 2019). A protective role 
for LCA is further supported by two recent studies in a canine 
model of chronic inflammatory enteropathy, where colonic 
inflammation was associated with decreased LCA levels and 
diet- or steroid-induced remission in this model was associ-
ated with increased stool LCA, but not UDCA, levels (Guard 
et al., 2019; Wang et al., 2019). Such a reciprocal relationship 
between LCA levels and the degree of mucosal injury sug-
gests a role for the bile acid as an endogenous suppressor gut 
inflammatory responses.
In conclusion, UDCA administration prevents cyto-
kine-induced epithelial apoptosis, promotes barrier function, 
and is protective in a mouse model of colonic inflammation. 
Bacterial metabolism of UDCA to LCA is required for such 
beneficial effects to be apparent. The molecular mechanisms 
by which LCA mediates its anti-apoptotic and anti-inflam-
matory actions remain to be identified and are the subject of 
ongoing work in our laboratory. While several possibilities 
exist, it is likely that LCA acts through one of the bile acid 
receptors known to be present in the colonic epithelium in-
cluding, FXR, TGR5, and VDR. Each of these receptors can 
be activated by LCA (Alemi et al., 2013; Ishizawa, Akagi, & 
Makishima, 2018; Zimber & Gespach, 2008), and each has 
been shown to exert protective actions in mouse models of 
colonic inflammation (Gadaleta et al., 2011; Ren et al., 2019; 
Wang et  al.,  2017). These receptors, along with therapeu-
tic strategies that appropriately modulate UDCA/LCA lev-
els in the colon, represent excellent opportunities for the 
development of new approaches to promote barrier function 
and prevent inflammation in patients with IBD.
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